← Back to headlines
ImmunityBio Stock Rises Amid FDA Review of Anktiva Label Expansion
ImmunityBio's stock saw a rise as its drug Anktiva underwent FDA review for a label expansion, indicating potential growth for the pharmaceutical company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
